229 related articles for article (PubMed ID: 33121449)
1. Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
Wei C; Li X
BMC Cancer; 2020 Oct; 20(1):1042. PubMed ID: 33121449
[TBL] [Abstract][Full Text] [Related]
2. Determination of the migration effect and molecular docking of verteporfin in different subtypes of breast cancer cells.
Wei C; Li X
Mol Med Rep; 2020 Nov; 22(5):3955-3961. PubMed ID: 32901856
[TBL] [Abstract][Full Text] [Related]
3. "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines".
Sanna L; Piredda R; Marchesi I; Bordoni V; Forcales SV; Calvisi DF; Bagella L
Chem Biol Interact; 2019 Oct; 312():108813. PubMed ID: 31494105
[TBL] [Abstract][Full Text] [Related]
4. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
Dong L; Lin F; Wu W; Liu Y; Huang W
Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
[TBL] [Abstract][Full Text] [Related]
5. Verteporfin inhibits growth of human glioma in vitro without light activation.
Al-Moujahed A; Brodowska K; Stryjewski TP; Efstathiou NE; Vasilikos I; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Sci Rep; 2017 Aug; 7(1):7602. PubMed ID: 28790340
[TBL] [Abstract][Full Text] [Related]
6. Verteporfin induces apoptosis and reduces the stem cell-like properties in Neuroblastoma tumour-initiating cells through inhibition of the YAP/TAZ pathway.
Fusco P; Mattiuzzo E; Frasson C; Viola G; Cimetta E; Esposito MR; Tonini GP
Eur J Pharmacol; 2021 Feb; 893():173829. PubMed ID: 33347823
[TBL] [Abstract][Full Text] [Related]
7. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation.
Brodowska K; Al-Moujahed A; Marmalidou A; Meyer Zu Horste M; Cichy J; Miller JW; Gragoudas E; Vavvas DG
Exp Eye Res; 2014 Jul; 124():67-73. PubMed ID: 24837142
[TBL] [Abstract][Full Text] [Related]
8. Molecular Features of the YAP Inhibitor Verteporfin: Synthesis of Hexasubstituted Dipyrrins as Potential Inhibitors of YAP/TAZ, the Downstream Effectors of the Hippo Pathway.
Gibault F; Bailly F; Corvaisier M; Coevoet M; Huet G; Melnyk P; Cotelle P
ChemMedChem; 2017 Jun; 12(12):954-961. PubMed ID: 28334506
[TBL] [Abstract][Full Text] [Related]
9. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
10. Platelet‑derived growth factor‑BB mediates pancreatic cancer malignancy via regulation of the Hippo/Yes‑associated protein signaling pathway.
Li T; Guo T; Liu H; Jiang H; Wang Y
Oncol Rep; 2021 Jan; 45(1):83-94. PubMed ID: 33416116
[TBL] [Abstract][Full Text] [Related]
11. Verteporfin can Reverse the Paclitaxel Resistance Induced by YAP Over-Expression in HCT-8/T Cells without Photoactivation through Inhibiting YAP Expression.
Pan W; Wang Q; Zhang Y; Zhang N; Qin J; Li W; Wang J; Wu F; Cao L; Xu G
Cell Physiol Biochem; 2016; 39(2):481-90. PubMed ID: 27383277
[TBL] [Abstract][Full Text] [Related]
12. Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells.
Dasari VR; Mazack V; Feng W; Nash J; Carey DJ; Gogoi R
Oncotarget; 2017 Apr; 8(17):28628-28640. PubMed ID: 28404908
[TBL] [Abstract][Full Text] [Related]
13. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
[TBL] [Abstract][Full Text] [Related]
14. YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma.
Vigneswaran K; Boyd NH; Oh SY; Lallani S; Boucher A; Neill SG; Olson JJ; Read RD
Clin Cancer Res; 2021 Mar; 27(5):1553-1569. PubMed ID: 33172899
[TBL] [Abstract][Full Text] [Related]
15. Verteporfin Suppresses YAP-Induced Glycolysis in Breast Cancer Cells.
Chen H; Zhang LF; Miao Y; Xi Y; Li X; Liu MF; Zhang M; Li B
J Invest Surg; 2023 Dec; 36(1):2266732. PubMed ID: 37828756
[TBL] [Abstract][Full Text] [Related]
16. YAP activation is an early event and a potential therapeutic target in liver cancer development.
Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
[TBL] [Abstract][Full Text] [Related]
17. Activated hippo signal pathway inhibits cell proliferation and promotes apoptosis in NK/T cell lymphoma cells.
Chang Y; Fu XR; Cui M; Li WM; Zhang L; Li X; Li L; Sun ZC; Zhang XD; Li ZM; You XY; Nan FF; Wu JJ; Wang XH; Zhang MZ
Cancer Med; 2019 Jul; 8(8):3892-3904. PubMed ID: 31124291
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Yes-Associated Protein by Verteporfin Ameliorates Unilateral Ureteral Obstruction-Induced Renal Tubulointerstitial Inflammation and Fibrosis.
Jin J; Wang T; Park W; Li W; Kim W; Park SK; Kang KP
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142952
[TBL] [Abstract][Full Text] [Related]
19. SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.
Isfort I; Cyra M; Elges S; Kailayangiri S; Altvater B; Rossig C; Steinestel K; Grünewald I; Huss S; Eßeling E; Mikesch JH; Hafner S; Simmet T; Wozniak A; Schöffski P; Larsson O; Wardelmann E; Trautmann M; Hartmann W
Clin Cancer Res; 2019 Jun; 25(12):3718-3731. PubMed ID: 30814111
[TBL] [Abstract][Full Text] [Related]
20. Verteporfin-loaded microparticles for radiosensitization of preclinical lung and breast metastatic spine cancer.
Akinduro OO; Suarez-Meade P; Roberts M; Tzeng SY; Sarabia-Estrada R; Schiapparelli P; Norton ES; Gokaslan ZL; Anastasiadis PZ; Guerrero-Cázares H; Green JJ; Quiñones-Hinojosa A
J Neurosurg Spine; 2023 Apr; 38(4):481-493. PubMed ID: 36585863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]